Hot Investor Mandate 2: Midwest Pharma Looking for Early Stage Partners in Inflammation, Cardiovascular and Oncology

29 Dec

A pharmaceutical company based in the Midwest is seeking early to mid-stage technology for equity, in-licensing, and acquisition opportunities, and typically invests $5M to $50M per project depending on the opportunity. In the past two years the company also acquired two US companies at $200-300M range. The company is seeking opportunities on a global level.

The firm is interested in early to mid-stage therapeutics in inflammatory diseases, cardiovascular diseases, diabetes, and cancer. The firm seeks preclinical to clinical stage pharmaceuticals with particular interest in large molecule biologics including naturally derived molecules and fermentation based products.

SPL has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: